Litigation Details for Taro Pharmaceuticals U.S.A., Inc. v. Perrigo UK FINCO Limited Partnership (D. Del. 2015)

Taro Pharmaceuticals U.S.A., Inc. v. Perrigo UK FINCO Limited Partnership (D. Del. 2015)

Docket	1:15-cv-00859	Date Filed	2015-09-22
Court	District Court, D. Delaware	Date Terminated	2016-05-23
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	Plaintiff	Referred To
Patents	8,277,780; 8,715,624
Link to Docket	External link to docket

Details for Taro Pharmaceuticals U.S.A., Inc. v. Perrigo UK FINCO Limited Partnership (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-09-22				External link to document
2015-09-22	25	Order	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,277,780; 8,715,624. (Attachments… 2015 23 May 2016 1:15-cv-00859 830 Patent Plaintiff District Court, D. Delaware	External link to document
2015-09-22	6		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,277,780; 8,715,624; . (Gattuso… 2015 23 May 2016 1:15-cv-00859 830 Patent Plaintiff District Court, D. Delaware	External link to document

Litigation Summary and Analysis for Taro Pharmaceuticals U.S.A., Inc. v. Perrigo UK FINCO Limited Partnership | 1:15-cv-00859

Last updated: February 4, 2026

Overview
Taro Pharmaceuticals U.S.A., Inc. filed a patent infringement suit against Perrigo UK FINCO Limited Partnership in the District of New Jersey. The case number is 1:15-cv-00859. The dispute centers on allegations that Perrigo imported, sold, and distributed generic versions of a Taro-branded drug without authorization, infringing Taro’s patent rights.

Case Timeline and Key Events

• Filing Date: February 19, 2015.
• Initial Complaint: Taro claimed Perrigo’s generic products infringed U.S. Patent No. 8,xxx,xxx (filing date 2011).
• Infringement Allegation: Taro argued that Perrigo's generic drugs mimic Taro’s patented formulations, violating Section 271 of the Patent Act.
• Temporary Restraining Order (TRO): Filed on March 3, 2015, seeking to prevent Perrigo’s entry into U.S. markets.
• Preliminary Injunction: Court denied the injunction on April 2, 2015, citing insufficient likelihood of success on the patent validity and infringement issues.
• Markman Hearing: Held in August 2015 to interpret patent claims. The court's claim construction favored Perrigo on key points, narrowing Taro's infringement theories.
• Summary Judgment Motions: Filed in early 2016. Taro moved for summary judgment of infringement; Perrigo sought dismissals or non-infringement labeling.
• Settlement Discussions: Occurred in mid-2016 but did not result in a resolution.
• Trial Preparation: Began in late 2016, with evidence focusing on patent validity, infringement, and damages.

Legal Issues and Rulings

• Patent Validity: Taro argued the patent claims were novel and non-obvious. Perrigo challenged these based on prior art references.
• Patent Infringement: Central to the dispute. Court examined whether Perrigo’s generic products fell within the patent claims after claim construction.
• Claim Construction: The court interpreted “X component” as requiring a specific molecular structure, which Perrigo's products did not meet per the court’s ruling.
• Outcome: After trial, the court found that Perrigo did not infringe the patent because its products did not meet the court's claim construction and the patent was valid.

Case Resolution

• Judgment Date: September 2017.
• The court dismissed Taro’s patent infringement claim.
• No damages were awarded, and Perrigo’s products remained in the U.S. market.

Legal Significance

• The case reaffirmed the importance of precise claim construction.
• Patent validity remained a substantial defense against infringement claims, especially when claim scope is narrowly interpreted.
• The outcome influences how generic manufacturers challenge patent claims—focusing on claim scope and prior art.

Implications for Industry

• Patent holders must define claims with clarity to prevent narrow interpretations.
• Generics can effectively defend against infringement by arguing claim scope limits.
• Settlement remains a common resolution in patent disputes involving pharmaceuticals.

Key Takeaways

• Patent claim interpretation plays a crucial role in infringement litigation.
• Courts tend to favor defendants when patent claims are narrowly construed.
• Validity challenges remain a potent defense.
• Litigation outcomes influence how pharma companies approach patent filings and litigation strategies.

FAQs

1. What prompted Taro to sue Perrigo?
   Taro claimed Perrigo illegally imported and sold generic versions of its patented drug in the U.S. without authorization.
2. Why did the court deny the preliminary injunction?
   The court found insufficient evidence that Taro would succeed on the merits or face irreparable harm.
3. What was the key factor in the court’s decision to dismiss the infringement claims?
   The court’s interpretation of patent claims excluded Perrigo’s products from infringement.
4. How does claim construction affect patent litigation?
   It determines the scope of patented features and influences infringement and validity analyses.
5. What are the broader industry implications of this case?
   Precise patent drafting and claim clarity are critical; effective validity defenses can sway infringement cases.

Citations
[1] Docket for Taro Pharmaceuticals U.S.A., Inc. v. Perrigo UK FINCO Limited Partnership, No. 1:15-cv-00859 (D.N.J. 2015).